18 results about "Viral hepatitis" patented technology

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The invention discloses application of licoflavone A in resisting viral hepatitis B, and belongs to the technical field of medicine application. The licoflavone A is used for treating viral hepatitis B. The licoflavone A used in the invention shows good safety and tolerance in HepG2.2. 15 and HepG2.A64 cells, can play a role in resisting HBV under the condition of no obvious cytotoxicity, and has significant advantages compared with interferon drugs in the prior art with long treatment course, large side effect and poor tolerance.

The application belongs to the technical field of biotechnology, and particularly relates to application of N-(quinoline-8-yl) quinoline-8-sulfonamide compounds in preparation of anti-hepatitis B virus drugs. The structure comprises as shown in (I) or a pharmaceutically acceptable salt thereof. The compound disclosed in the application has good inhibitory effect on HBV virus replication at the level of HBV infection model cells such as HepG2.2.15 and Huh7-NTCP, has anti-hepatitis virus activity, provides a good choice for treating viral hepatitis, and also has important significance for developing more ideal hepatitis B treatment drugs.

The present application belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition with the effect of preventing and / or treating hepatitis B. The traditional Chinese medicine composition is mainly prepared from Notopterygium incisum, Angelica pubescens, Poria cocos, Saposhnikovia divaricata, Schizonepeta tenuifolia, Chuanxiong, Platycodon grandiflorum, Bupleurum chinense, Peucedanum praeruptorum, Citrus aurantium, and Glycyrrhiza uralensis. The traditional Chinese medicine composition can not only significantly inhibit the activity of hepatitis B virus, but also significantly inhibit the secretion of HBSAg and HBeAg of hepatitis B virus, inhibit rebound after drug withdrawal, has a significant preventive and / or therapeutic effect on liver damage caused by hepatitis B virus infection, and can promote the production of hepatitis B surface antibody, thus having a broad clinical application prospect.

The invention discloses a preparation method of alpha-ketoisovaleric acid in an anti-hepatic fibrosis drug, and relates to the technical field of hepatic fibrosis treatment drug development, and the preparation method comprises the following steps: mixing alpha-ketoisovaleric acid with pharmaceutic adjuvants to prepare a pharmaceutically acceptable dosage form; the dosage of the alpha-ketoisovaleric acid is determined based on the pharmacological activity of the alpha-ketoisovaleric acid in the concentration range of 50 mu M to 200 mu M, wherein the alpha-ketoisovaleric acid can inhibit hepatic stellate cell activation induced by a transforming growth factor-beta; an endogenous metabolite alpha-ketoisovaleric acid is applied to preparation of an anti-hepatic fibrosis medicine, and based on the pharmacological activity of the alpha-ketoisovaleric acid for specifically inhibiting activation of TGF-beta induced hepatic stellate cells at the concentration of 50-200 mu M, a novel anti-hepatic fibrosis preparation which is high in safety, wide in therapeutic window and free of liver and kidney accumulation risk is developed. The medicine is not only suitable for treating hepatic fibrosis caused by various causes such as non-alcoholic fatty liver disease, viral hepatitis, alcoholic liver disease and drug-induced liver injury, but also meets the requirements of early intervention and severe treatment through reasonable dosage form design and administration route selection.

The invention relates to the technical field of microorganisms, in particular to a highly pathogenic duck virus hepatitis III virus and an egg yolk antibody, preparation and application thereof. The virus strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 24, 2024, the preservation number is CGMCC No.46271, and the virus strain is named as RD240820B. The egg yolk antibody is prepared by using the highly pathogenic duck virus hepatitis III type virus strain as an antigen. The egg yolk antibody is applied to preparation of products for preventing or treating duck virus hepatitis III. In a virulence experiment on a duck embryo, the death rate of the virus strain reaches 80% after the duck embryo is inoculated for 36 hours, and the virus strain has strong pathogenicity. And the death rate within 60 hours after inoculation is 100%, and the strain has relatively strong pathogenicity. The death rate is still 60% when the diluent is 10-8, and the toxicity is strong. The ELD50 value of the strain is relatively low, which indicates that the strain has relatively strong pathogenicity to duck embryos. After the egg yolk antibody is injected, the protection rate reaches up to 97.6% after the diseased duck is treated, and the egg yolk antibody has a remarkable prevention and control effect.

The invention belongs to the technical field of biology, and particularly relates to a recombinant baculovirus capable of simultaneously expressing gene type 1 and gene type 3 duck hepatitis A virus VP1 protein and application of the recombinant baculovirus in preparation of a duck hepatitis A divalent subunit vaccine. The recombinant baculovirus co-expressing the gene type 1 and gene type 3 duck hepatitis A virus VP1 protein is constructed, the virus titer is high, and the two proteins can be expressed. Therefore, the recombinant baculovirus provided by the invention can be used for research and development and epidemic disease prevention and control of novel vaccines for duck viral hepatitis A.

The invention discloses a composite liver and kidney protective agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The protective agent is prepared from 10%-20% of inosine, 15%-25% of glutamic acid, 10%-15% of cysteine, 15%-20% of glycine, 5%-10% of a coenzyme compound, 10%-20% of small molecule peptide and auxiliary materials. The preparation method comprises the steps of premixing, low-temperature homogenization, spray drying and preparation forming, and uniform distribution of components is ensured through a spray drying technology. The traditional Chinese medicine composition plays a role through a three-stage mechanism of fat removal, repair and regeneration, reduces lipid deposition, scavenges free radicals, repairs hepatocytes and promotes regeneration. The traditional Chinese medicine composition can be used for treating or preventing liver and kidney diseases such as non-alcoholic fatty liver, viral hepatitis and cirrhosis, relieving symptoms such as anorexia, jaundice and bleeding, dispelling the effects of alcohol, protecting the liver and enhancing immunity. The proportion of natural components of the protective agent is more than 80%, the safety is high, multiple targets are synergistic, and the curative effect is superior to that of a single-component medicine.

The application discloses a composition for preventing non-viral hepatitis and a preparation method and application thereof, and belongs to the technical field of food processing. The composition comprises a crude peptide, and the amino acid sequence of the crude peptide is Ile-Val-Tyr-Pro-Trp-Thr-Gln-Arg; further comprises lipids and excipients; the crude peptide and the lipids form a water-in-oil emulsion system; and the emulsion system and the excipients are mixed to form the composition. Experiments prove that the composition prepared by the application has the effect of improving non-viral hepatitis, and provides a new way for the prevention and treatment of non-viral hepatitis.

This invention relates to a novel use of synephrine in the preparation of drugs for treating cholestatic liver disease, belonging to the field of pharmaceutical technology. Cholestatic liver disease is characterized by jaundice and conjugated bilirubin and / or total bilirubin hyperconjugation caused by impaired bilirubin excretion due to various reasons. Its causes include common bile duct stones, pancreatic duct cancer, common bile duct malignant tumors, pancreatic cancer, biliary parasitic diseases, viral hepatitis cirrhosis, alcoholic liver disease, fatty liver disease, drug-induced liver injury, primary biliary cirrhosis, intrahepatic sclerosing cholangitis, and certain congenital diseases such as Dubin-Johnson syndrome and Rotor syndrome. This invention establishes a mouse cholestasis model using bile duct ligation and administers synephrine by gavage to evaluate its protective effect against liver injury. The results showed that synephrine significantly improved jaundice caused by cholestasis, reduced hepatocellular necrosis and inflammatory infiltration caused by cholestasis, alleviated bile duct dilation, decreased serum total bilirubin (TBIL) and direct bilirubin (DBIL), and reduced the levels of total bile acids (BA) in liver tissue and plasma. Furthermore, the above-mentioned effects of synephrine in improving cholestasis showed a clear dose-dependent effect. This invention reveals for the first time the application of synephrine in cholestatic liver disease, demonstrating good safety and promising clinical development prospects.

The invention discloses an application of alzovudine in resisting viral hepatitis B, and belongs to the technical field of medicine application. The alzovudine is used for treating and resisting viral hepatitis B. An in-vivo and in-vitro combined efficacy verification system is established, a multi-genotype and drug-resistant mutation HBV model is covered, experimental results are stable and repeatable, and screening and evaluation of novel nucleoside anti-HBV drugs can be effectively guided. The invention reveals that the FNC has the comprehensive technical advantages of broad-spectrum virus resistance, drug-resistant mutation resistance, strong antigen removal capability, high safety and the like in the treatment of hepatitis B virus infection, breaks through the bottleneck that the existing NAs has limited curative effect and the antigen is difficult to remove, and provides a new candidate drug and a technical route for functional cure of chronic hepatitis B.

The invention discloses an application of a fortune euonymus herb chemical fiber formula in treatment of hepatic fibrosis, and relates to the field of biological medicines. According to the present invention, the anti-hepatic fibrosis effect is provided by inhibiting hepatic stellate cell activation and reducing extracellular matrix deposition, and the hepatic fibrosis is the chronic liver injury pathological stage caused by viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease or drug-induced liver injury; in an in-vitro experiment, the euonymus fortunei chemical fiber formula also plays a role in resisting hepatic fibrosis by inhibiting a transient receptor potential vanillic acid subtype 4 signal channel. The method has the following comprehensive advantages that (1) HSC activation and ECM deposition are inhibited through multi-component and multi-target cooperation; (2) key signal channels such as TGF-beta1 / Smad, TRPV4 and the like can be regulated and controlled at the same time; (3) liver function indexes are obviously improved, and tissue structure damage is relieved; and (4) the medicine is natural in source, high in safety and suitable for long-term application.

The application belongs to the technical field of medicine, and particularly relates to application of a jingfang preparation in prevention or treatment of type A viral hepatitis. Pharmacological experiments show that the jingfang preparation has a significant inhibitory effect on serum HAV-DNA level of infected ducks, can significantly inhibit the activity of type A hepatitis virus, and can be used for prevention and treatment of type A viral hepatitis, has a definite clinical curative effect, and is superior to jingfang baidu powder with modifications, and has a broad clinical application prospect.

The invention relates to mutations and alterations in the inflammatory pathway, including IL-18BP and IL-10RB mutations, that are associated with the development of fulminant viral hepatitis following viral infection, such as following hepatitis virus infection. The invention relates to methods for treating or ameliorating viral hepatitis comprising administering IL-18BP, IL-18 antagonist, IFNγ antagonist or inhibitor, and / or IL-10RB or an IL-10 antagonist.

The present application provides a composition for treating hepatitis C and a preparation method thereof. The composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition or capsule can effectively treat hepatitis C, and the preparation process is simple, safe, stable, and has rapid dissolution.

The invention discloses a prediction method for differential diagnosis of autoimmune hepatitis based on ASGPR and a related product thereof, and relates to the field of biological diagnosis. The invention provides a novel marker which can be used for evaluating the risk of the autoimmune hepatitis of a subject, so that the detection sensitivity and specificity of the autoimmune hepatitis can be remarkably improved, and the missed diagnosis and misdiagnosis rates are effectively reduced; effective identification of AIH and other liver diseases (such as viral hepatitis, drug-induced liver injury, metabolic fatty liver and the like) or healthy people can be realized, and a detection kit or a prediction method developed based on the marker has the advantages of simplicity and convenience in operation, high flux and controllable cost, is easy to popularize in clinical practice and has a wide application prospect. Therefore, the early discovery rate of the autoimmune hepatitis and the timeliness of treatment intervention are greatly improved.